Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 220 participants.
Also called NCT06858319
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 220 participants
- Sponsor
- Registry
-
NCT06858319
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Canada, Malaysia, Mexico, South Korea, Spain, Taiwan
- Registry status
- Recruiting
Technical summary
Registry record NCT06858319. Allocation not applicable; no masking; primary purpose treatment. Start 2025-07-28 (actual); primary completion 2031-06-25 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
- Condition
- Kidney Diseases
- Condition
- Kidney Diseases, Chronic
- Condition
- Urological Diseases
- Condition
- Glomerulonephritis
- Condition
- Glomerular Disease
- Condition
- Glomerulonephritis, IGA
- Condition
- Glomerulopathy
- Condition
- Immunoglobulin Disease
- Intervention (Drug)
- zigakibart
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct06858319- Content hash
44a1621ad617307df6c171327efcc47f40aad5d5dece26413bf276a71c304e03